20:34 , Jul 14, 2017 |  BioCentury  |  Strategy

Back to Ipsen’s roots

After spending the last six years plugging revenue holes via licensing and M&A, Ipsen Group is once again on track to meet the 2020 financial targets it set at the beginning of the decade. But...
07:00 , Aug 4, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Neurotensin (NTS)-based PET imaging agents for diagnosing and monitoring treatment responses of neurotensin receptor 1 (NTSR1)-positive tumors

Imaging TECHNOLOGY: PET Neurotensin-based PET imaging agents could help diagnose and monitor treatment-response for NTSR1-positive cancers. Two agents, consisting of a six-amino acid peptide derived from the N-terminus of neurotensin conjugated via linkers to a 68Ga radionuclide,...
07:00 , May 26, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Neurotensin (NTS); neurotensin receptor 1 (NTSR1); proneurotensin

Endocrine/metabolic disease INDICATION: Obesity Human sample and mouse studies suggest inhibiting NTS-NTSR1 signaling could help treat obesity. In 4,632 obesity patients and healthy volunteers, high fasting plasma levels of the NTS precursor proneurotensin were associated with obesity...
08:00 , Dec 4, 2014 |  BC Innovations  |  Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc., Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations to...
07:00 , May 27, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Neurotensin receptor 1 (NTSR1); NTSR2 A study in rats identified a derivative of an analgesic neurotensin...
07:00 , May 21, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Gastrointestinal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease ...